ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ANI Pharmaceuticals, Inc. ?
1
The company is Net-Debt Free
2
Healthy long term growth as Net Sales has grown by an annual rate of 33.48%
3
With a growth in Net Sales of 12.04%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 189.48 MM
- ROCE(HY) Highest at 19.33%
- INVENTORY TURNOVER RATIO(HY) Highest at 3.36 times
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to ANI Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ANI Pharmaceuticals, Inc. for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
ANI Pharmaceuticals, Inc.
-21.92%
0.64
30.97%
S&P 500
15.76%
1.22
13.15%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
33.48%
EBIT Growth (5y)
48.48%
EBIT to Interest (avg)
-0.55
Debt to EBITDA (avg)
36.46
Net Debt to Equity (avg)
1.18
Sales to Capital Employed (avg)
0.66
Tax Ratio
23.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.20%
ROE (avg)
1.25%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
3.03
EV to EBIT
24.17
EV to EBITDA
11.37
EV to Capital Employed
2.27
EV to Sales
2.22
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
9.39%
ROE (Latest)
8.30%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 189.48 MM
ROCE(HY)
Highest at 19.33%
INVENTORY TURNOVER RATIO(HY)
Highest at 3.36 times
PRE-TAX PROFIT(Q)
Highest at USD 35.73 MM
RAW MATERIAL COST(Y)
Fallen by -2.43% (YoY
CASH AND EQV(HY)
Highest at USD 701.97 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 3.91 times
NET SALES(Q)
Highest at USD 266.04 MM
NET PROFIT(Q)
At USD 22.09 MM has Grown at 41.18%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for ANI Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 189.48 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
Highest at USD 35.73 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Inventory Turnover Ratio
Highest at 3.36 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Net Sales
Highest at USD 266.04 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 35.73 MM has Grown at 62.07%
over average net sales of the previous four periods of USD 22.05 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 22.09 MM has Grown at 41.18%
over average net sales of the previous four periods of USD 15.65 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 701.97 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 3.91 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -2.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
